AVE 0.00% 0.3¢ avecho biotechnology limited

Last night, I sat in on a webinar run by Musculoskeletal...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,650 Posts.
    lightbulb Created with Sketch. 777
    Last night, I sat in on a webinar run by Musculoskeletal Australia.
    Prof. Iain McGregor from the Lambert Insitute presented it.
    Unfortunately, I wasn't able to take notes. However, a few things stood out.
    The majority of the presentation focussed on medicinal cannabis. Its primary focus was on Pain.
    He did speak about the evidence that is there for each ailment. Interestingly, it spoke about there being an increased amount of evidence for CBD to be used as a treatment for anxiety. I think this is a secondary endpoint for the Phase 3 clinical trial. He directly mentioned Avecho twice. Once for the sleep trial and once for the topical gel trial.
    He also spoke a great deal about the use of cbg? I think it was. It's another form of cannabinoid that looks like it has great potential, and I think Avecho has been involved in it.
    There is meant to be a recording of the video. If I find it, I will post it here.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.